Browsing by Author "Tan, Maria M. (57209849735)"
Now showing 1 - 2 of 2
- Results Per Page
- Sort Options
- Some of the metrics are blocked by yourconsent settings
Publication Cognitive and behavioral improvement in adults with fragile X syndrome treated with metformin-two cases(2019) ;Protic, Dragana (18635502600) ;Aydin, Elber Y. (57209848720) ;Tassone, Flora (7006128050) ;Tan, Maria M. (57209849735) ;Hagerman, Randi J. (7006679292)Schneider, Andrea (56910354900)Background: The majority of individuals with fragile X syndrome (FXS) have intellectual disability, behavioral problems, autism, and language deficits. IQ typically declines with age in boys with the full mutation. The results of preclinical studies demonstrated that metformin, a biguanide used to treat type 2 diabetes, rescues multiple phenotypes of FXS in both Drosophila and mouse models. Preliminary studies of patients with FXS demonstrated improvements in behavior. Methods: Here, we present two cases of individuals who have been treated with metformin clinically for one year. Results: Both patients demonstrated significant cognitive and behavioral improvements. They also improved eating habits and normalization of their weight percentiles. Conclusion: Metformin may be a candidate drug for treatment of several types of symptoms in individuals with FXS. © 2019 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals, Inc. - Some of the metrics are blocked by yourconsent settings
Publication Cognitive and behavioral improvement in adults with fragile X syndrome treated with metformin-two cases(2019) ;Protic, Dragana (18635502600) ;Aydin, Elber Y. (57209848720) ;Tassone, Flora (7006128050) ;Tan, Maria M. (57209849735) ;Hagerman, Randi J. (7006679292)Schneider, Andrea (56910354900)Background: The majority of individuals with fragile X syndrome (FXS) have intellectual disability, behavioral problems, autism, and language deficits. IQ typically declines with age in boys with the full mutation. The results of preclinical studies demonstrated that metformin, a biguanide used to treat type 2 diabetes, rescues multiple phenotypes of FXS in both Drosophila and mouse models. Preliminary studies of patients with FXS demonstrated improvements in behavior. Methods: Here, we present two cases of individuals who have been treated with metformin clinically for one year. Results: Both patients demonstrated significant cognitive and behavioral improvements. They also improved eating habits and normalization of their weight percentiles. Conclusion: Metformin may be a candidate drug for treatment of several types of symptoms in individuals with FXS. © 2019 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals, Inc.
